<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr Neurosci</journal-id><journal-id journal-id-type="publisher-id">JPN</journal-id><journal-title-group><journal-title>Journal of Pediatric Neurosciences</journal-title></journal-title-group><issn pub-type="ppub">1817-1745</issn><issn pub-type="epub">1998-3948</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21042500</article-id><article-id pub-id-type="pmc">2964805</article-id><article-id pub-id-type="publisher-id">JPN-5-18</article-id><article-id pub-id-type="doi">10.4103/1817-1745.66673</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Role of hypertonic saline and mannitol in the management of raised intracranial pressure in children: A randomized comparative study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Upadhyay</surname><given-names>Piyush</given-names></name><xref ref-type="aff" rid="AF0001"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Tripathi</surname><given-names>V. N.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>R. P.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Sachan</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib></contrib-group><aff id="AF0001">Pediatric Intensive Care Unit, Department of Pediatrics, GSVM Medical College, Kanpur (U.P.), India</aff><author-notes><corresp id="cor1"><bold>Address for Correspondence:</bold> Dr. Piyush Upadhyay, 4/135, Vishesh Khand, Gomti Nagar, Lucknow, U.P., India. E-mail: <email xlink:href="piyushdrpeds.com@gmail.com">piyushdrpeds.com@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Jun</season><year>2010</year></pub-date><volume>5</volume><issue>1</issue><fpage>18</fpage><lpage>21</lpage><permissions><copyright-statement>&#x000a9; Journal of Pediatric Neurosciences</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To compare the efficacy and side effects of 3% hypertonic saline and mannitol in the management of raised intracranial pressure in children.</p></sec><sec id="st2"><title>Design:</title><p>Prospective randomized study.</p></sec><sec id="st3"><title>Setting:</title><p>Pediatric intensive care unit (PICU) in a tertiary care hospital.</p></sec><sec id="st4"><title>Subject:</title><p>200 patients with raised intracranial pressure.</p></sec><sec id="st5"><title>Materials and Methods:</title><p>Patients were randomized into two statistically comparable groups; Group A (n = 98) was treated with mannitol while Group B (n = 100) was treated with 3% hypertonic saline. Group C (n = 2) included those members of Group A in whom serum osmolality &#x02265;320 mosmol/kg and were then treated with 3% hypertonic saline. Both Drugs were given at a loading dose of 5 ml/kg stat followed by 2 ml/kg in every 6 h(both have same osmolarity) for two days in their respective groups. Besides monitoring, blood pressure (NIBP), mean arterial pressure (pre and post 30 min of drug), serum sodium, chloride and osmolality were measured. Intracranial pressure was assessed indirectly by measuring mean arterial ressure &#x0201c;MAP&#x0201d;. Student paired &#x02018;t&#x02019; test was applied.</p></sec><sec id="st6"><title>Results:</title><p>Decrease in MAP was highly significant (<italic>P</italic>&#x0003c;0.001) at 0 h in males 0,6 h in females, and moderately significant at 12,36 h in females and significant(<italic>P</italic>&#x0003c;0.05) at 6,24,42 h in males of Group B. Decrease in coma hours was a highly significant finding (<italic>P</italic>&#x0003c;0.001) in Group B. In Group B, serum sodium and chloride increased significantly but remained within acceptable limits. There was no difference in osmolality and mortality (fisher Z).</p></sec><sec id="st7"><title>Conclusion:</title><p>Mannitol has several side effects, 3% hypertonic saline is a safe and effective alternative in managing cerebral edema.</p></sec></abstract><kwd-group><kwd>Hypertonic saline</kwd><kwd>mannitol</kwd><kwd>raised intracranial pressure</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Hyperosmolar treatment is one of the important methods for treating cerebral edema, and has been employed since early 1960. Urea, glycerol and mannitol were used for the treatment of this condition in the early years, but urea and glycerol were soon abandoned because of low efficacy. Mannitol is still used extensively. Side effects such as rebound effect, serum electrolyte imbalance and hypovolemia have led to the continued search for other osmotically active agents. One of them is hypertonic saline.</p><sec id="sec2-1"><title>Aims and objectives</title><p>To study the efficacy of hypertonic saline in the treatment of raised intracranial pressure in children in comparison to mannitol.</p><p>To study the side effects (if any) of hypertonic saline treatment in the management of raised intracranial pressure.</p></sec></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p><list list-type="bullet"><list-item><p><bold>Study design:</bold> Prospective randomized comparative study</p></list-item><list-item><p><bold>Setting:</bold> Pediatric intensive care unit (PICU)</p></list-item><list-item><p><bold>Data analysis:</bold> Continuous data was analyzed by using Student unpaired &#x02018;t&#x02019; test</p></list-item><list-item><p><bold>Inclusion criteria:</bold> 200 Children aged 2 to 18 years, admitted to the emergency Department of Pediatrics between Jan 15th, 2007 and May 31<sup>st</sup>, 2008 with clinical symptoms and signs of raised intracranial pressure.</p></list-item></list></p><p><list list-type="bullet"><list-item><p><bold>Exclusion criteria</bold></p><p>Patients with:</p><list list-type="bullet"><list-item><p>compromised renal function (increased Serum creatinine)</p></list-item><list-item><p>hepatic encephalopathy</p></list-item><list-item><p>serum Na+ (&#x0003e;150 meq/l)</p></list-item><list-item><p>diabetic ketoacidosis</p></list-item><list-item><p>cerebral malaria</p></list-item></list></list-item></list></p><sec id="sec2-2"><title>Groups and method of randomization</title><p>Group A (those admitted on Wednesday, Thursday, Friday, <italic>n</italic> = 98): treated with mannitol</p><p>Group B (those admitted on Monday, Tuesday, Saturday, <italic>n</italic>=100): treated with 3% hypertonic saline.</p><p>Group C (<italic>n</italic> = 2) was later made and Included those members of Group A in whom S. osmolality increased to more than 320 mOsm / kg and were then treated with 3% hypertonic saline.</p></sec><sec id="sec2-3"><title>Intervention protocol</title><p>Loading dose(5ml/kg) was followed by maintenance dose (2 ml/kg) in every 6 h in both groups for two days (osmolarity of mannitol and 3% hypertonic saline are almost same i.e. 1100 mOsm/l and 1098 mOsm/l, respectively).</p></sec><sec id="sec2-4"><title>Measurements taken</title><p><bold>Blood pressure:</bold> By NIBP, at admission and then in every 6 h, both pre and post drug (30 min of 3% hypertonic saline or mannitol therapy).</p><p><bold>S. creatinine:</bold> Before starting treatment and after 48 h.</p><p><bold>Blood urea nitrogen:</bold> Before starting treatment and after 48 h.</p><p><bold>Serum electrolytes:</bold> Before starting treatment and then in every 12 h.</p><p><bold>ABG:</bold> Before starting treatment, and after 12, 24, 36 and 48 h.</p></sec><sec id="sec2-5"><title>CT scan (or MRI when needed) of head</title><p>Comparison of average reduction of mean arterial pressure (pre and post drug) at definite time (6h) intervals was done to indirectly assess reduction in intracranial pressure.</p><p>Mean arterial pressure indirectly represents intracranial pressure</p><p>(Cerebral perfusion pressure (CPP) = mean arterial pressure &#x02013; intra cranial pressure (ICP) i.e. MAP = CPP + ICP (where CPP remains constants)</p><p>Formula applied: MAP &#x003b1; ICP</p></sec></sec><sec id="sec1-3"><title>Results</title><p><list list-type="bullet"><list-item><p>3% hypertonic saline was more efficacious than mannitol in the initial 12 h and equally or more efficacious than mannitol therapy later.</p></list-item><list-item><p>Decrease in coma hours was a significant additional finding in the group treated with 3% hypertonic saline (Group B).</p></list-item><list-item><p>Change in blood biochemistry was within acceptable limits in Group B. [Tables <xref ref-type="table" rid="T0001">1</xref>&#x02013;<xref ref-type="table" rid="T0005">5</xref>]</p></list-item></list></p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Age and Sex wise distribution of trial groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="center" rowspan="1" colspan="1">Mean age (mths)</th><th align="center" colspan="2" rowspan="1">Female<hr/></th><th align="center" colspan="2" rowspan="1">Male<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">No. of cases(n)</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">No. of cases(n)</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">67.9</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">68.4</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">61</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">70.5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">60</td></tr></tbody></table><table-wrap-foot><fn><p>Age and sex distribution between A &#x00026; B trial groups was comparable</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Etiological distribution of trial group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Etiology</th><th align="center" rowspan="1" colspan="1">Group A</th><th align="center" rowspan="1" colspan="1">Group B</th><th align="center" rowspan="1" colspan="1">Group C</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Meningoencephalitis</td><td align="center" rowspan="1" colspan="1">73 (74.48)</td><td align="center" rowspan="1" colspan="1">75 (75)</td><td align="center" rowspan="1" colspan="1">2 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurocysticercosis (Anoxic Encephalopathy)</td><td align="center" rowspan="1" colspan="1">12 (12.24)</td><td align="center" rowspan="1" colspan="1">8 (8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Head trauma</td><td align="center" rowspan="1" colspan="1">6 (6.12)</td><td align="center" rowspan="1" colspan="1">8 (8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Space occupying lesion</td><td align="center" rowspan="1" colspan="1">5 (5.10)</td><td align="center" rowspan="1" colspan="1">5 (5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Global Infarction</td><td align="center" rowspan="1" colspan="1">2 (2.04)</td><td align="center" rowspan="1" colspan="1">4 (4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total (n)%</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">100 (100)</td><td align="center" rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn><p>Thus etiological distribution in group A&#x00026;B were found to be comparable, Figures in the parentheses are in percentage</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Comparison of various parameters between group A &#x00026; B</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter (X&#x000b1;SD)</th><th align="center" rowspan="1" colspan="1">Group A</th><th align="center" rowspan="1" colspan="1">Group B</th><th align="center" rowspan="1" colspan="1">Group C</th><th align="center" rowspan="1" colspan="1">&#x02018;t&#x02019; value</th><th align="center" rowspan="1" colspan="1">&#x02018;<italic>P</italic>&#x02019; value</th><th align="center" rowspan="1" colspan="1">Inference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">S. Osm (mosm/kg)</td><td align="center" rowspan="1" colspan="1">310&#x000b1;4.3 (285-319)</td><td align="center" rowspan="1" colspan="1">308&#x000b1;5.6 (288-322)</td><td align="center" rowspan="1" colspan="1">330&#x000b1;8.4 (324-336)</td><td align="center" rowspan="1" colspan="1">1.41</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">S.Na (meq/l)</td><td align="center" rowspan="1" colspan="1">128&#x000b1;2.4 (123-130)</td><td align="center" rowspan="1" colspan="1">136&#x000b1;6.2 (122-153)</td><td align="center" rowspan="1" colspan="1">138&#x000b1;8.4 (132-144)</td><td align="center" rowspan="1" colspan="1">6.20</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">Highly Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of coma (hrs)</td><td align="center" rowspan="1" colspan="1">98.6&#x000b1;21.25 (28-138)</td><td align="center" rowspan="1" colspan="1">77.50&#x000b1;13.05 (24-144)</td><td align="center" rowspan="1" colspan="1">123&#x000b1;18.3 (110-136)</td><td align="center" rowspan="1" colspan="1">8.40</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">Highly Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">S.Chloride (mmol/l)</td><td align="center" rowspan="1" colspan="1">96.0&#x000b1;1.3 (85-99)</td><td align="center" rowspan="1" colspan="1">102&#x000b1;1.6 97-106)</td><td align="center" rowspan="1" colspan="1">100&#x000b1;2 (98-104)</td><td align="center" rowspan="1" colspan="1">3.00</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Mortality</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Z=0.34 Fisher Z</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr></tbody></table></table-wrap><table-wrap id="T0004" position="float"><label>Table 4</label><caption><p>Relationship between group A and group B male subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Hrs</th><th align="center" rowspan="1" colspan="1">Group A (X&#x000b1;SD)</th><th align="center" rowspan="1" colspan="1">Group B (X&#x000b1;SD)</th><th align="center" rowspan="1" colspan="1">&#x02018;t&#x02019; value</th><th align="center" rowspan="1" colspan="1">&#x02018;<italic>P</italic>&#x02019; value</th><th align="center" rowspan="1" colspan="1">Significance of B</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">7&#x000b1;3.25</td><td align="center" rowspan="1" colspan="1">11.5&#x000b1;4.48</td><td align="center" rowspan="1" colspan="1">6.33</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">Highly Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">7&#x000b1;2.58</td><td align="center" rowspan="1" colspan="1">8.2&#x000b1;3.52</td><td align="center" rowspan="1" colspan="1">2.14</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">5.7&#x000b1;1.62</td><td align="center" rowspan="1" colspan="1">5.4&#x000b1;1.97</td><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">6.6&#x000b1;2.89</td><td align="center" rowspan="1" colspan="1">6.1&#x000b1;2.6</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">6.2&#x000b1;2.56</td><td align="center" rowspan="1" colspan="1">5&#x000b1;2.51</td><td align="center" rowspan="1" colspan="1">2.60</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.7&#x000b1;2.14</td><td align="center" rowspan="1" colspan="1">4&#x000b1;2.59</td><td align="center" rowspan="1" colspan="1">1.62</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">3.3&#x000b1;2.58</td><td align="center" rowspan="1" colspan="1">3.6&#x000b1;2.25</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">2&#x000b1;2.19</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;2.45</td><td align="center" rowspan="1" colspan="1">2.00</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">2&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">1.9&#x000b1;1.14</td><td align="center" rowspan="1" colspan="1">0.37</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr></tbody></table><table-wrap-foot><fn><p>X=mean of differnce between pre and post drug mean map at definite time intervals</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0005" position="float"><label>Table 5</label><caption><p>Relationship between group A and group B female subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Hrs</th><th align="center" rowspan="1" colspan="1">Group A) (X&#x000b1;SD)</th><th align="center" rowspan="1" colspan="1">Group B (X&#x000b1;SD)</th><th align="center" rowspan="1" colspan="1">&#x02018;t&#x02019; value</th><th align="center" rowspan="1" colspan="1">&#x02018;<italic>P</italic>&#x02019; value</th><th align="center" rowspan="1" colspan="1">Significance of B</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">7&#x000b1;1.88</td><td align="center" rowspan="1" colspan="1">8.2&#x000b1;1.74</td><td align="center" rowspan="1" colspan="1">4.80</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">Highly Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5.8&#x000b1;1.16</td><td align="center" rowspan="1" colspan="1">4.4&#x000b1;2.02</td><td align="center" rowspan="1" colspan="1">3.15</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">Highly Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">5.0&#x000b1;1.47</td><td align="center" rowspan="1" colspan="1">6.1&#x000b1;1.80</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">Moderate Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;1.18</td><td align="center" rowspan="1" colspan="1">3.3&#x000b1;1.99</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">3.4&#x000b1;1.91</td><td align="center" rowspan="1" colspan="1">4.0&#x000b1;2.06</td><td align="center" rowspan="1" colspan="1">1.36</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.6&#x000b1;1.17</td><td align="center" rowspan="1" colspan="1">3.38&#x000b1;1.06</td><td align="center" rowspan="1" colspan="1">3.20</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">Moderate Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">4.2&#x000b1;1.20</td><td align="center" rowspan="1" colspan="1">4.35&#x000b1;1.27</td><td align="center" rowspan="1" colspan="1">0.55</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1;1.73</td><td align="center" rowspan="1" colspan="1">3.0&#x000b1;1.60</td><td align="center" rowspan="1" colspan="1">1.35</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">1.6&#x000b1;1.33</td><td align="center" rowspan="1" colspan="1">1.30&#x000b1;0.56</td><td align="center" rowspan="1" colspan="1">1.36</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">Not Significant</td></tr></tbody></table><table-wrap-foot><fn><p>X=mean of differnce between pre and post drug mean map at definite time intervals</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>For the first time, in 1919, Weed and McKibben[<xref ref-type="bibr" rid="CIT2">2</xref>] reported in animal models that HS results in a change in the brain volume. However, HS failed to attract the interest and field of application it deserved. In the early 1980&#x02019;s, its positive effects were shown in patients with hemorrhagic shock.[<xref ref-type="bibr" rid="CIT3">3</xref>] Later, it was employed in animal models with traumatic cerebral edema and shown to be superior than mannitol in reducing intracranial pressure (ICP) and fluid content of brain.[<xref ref-type="bibr" rid="CIT4">4</xref><xref ref-type="bibr" rid="CIT5">5</xref>] These experimental findings gave encouragement for application to patients with cerebral edema of traumatic origin. Worthley, <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT7">7</xref>] demonstrated reduction in ICP and increase in systemic perfusion with a 30% saline given as a single bolus in two traumatic mannitol resistant patients. Like-wise, in a few uncontrolled studies HS at 3-23.4% has been shown to reduce the ICP after head trauma.[<xref ref-type="bibr" rid="CIT8">8</xref><xref ref-type="bibr" rid="CIT9">9</xref>]</p><p>During the period in which mannitol was used intensively, maintenance of serum osmolarity below 320 mOsm/l was recommended because of complications of acute tubular necrosis (ATN) and renal failure. However, it was later understoodthat this complication developed as a result of dehydration and hypovolemia.[<xref ref-type="bibr" rid="CIT10">10</xref>] Children have been found to tolerate well the rather high serum osmolarity (365 mOsm/l) due to HS.[<xref ref-type="bibr" rid="CIT11">11</xref><xref ref-type="bibr" rid="CIT12">12</xref>] Owing to its diuretic effect and the consequent risk of development of hypovolemia, mannitol has a greater risk of being complicated by ATN than HS. Comparative studies with mannitol have also been conducted and published. In a prospective, randomized study, Vialet, <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT13">13</xref>] showed that HS at 7.5% concentration administered as an isovolemic bolus (2 ml/kg) was more effective than 20% mannitol in reducing the ICP in trauma patients. Another prospective study conducted by Horn, <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT14">14</xref>] using 7.5% saline administered as bolus infusion to patients with elevated ICP due to trauma and not responding to the standard treatment showed that it was effective in reducing the ICP and CPP. With the aim of reducing the ICP to below 20 mmHg, Peterson, <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT11">11</xref>] administered a 3% saline infusion to 68 children with trauma who did not respond to standard treatment. They found serum-Na concentrations of 150-170 mEq/l and a serum osmolarity of 300-330 mOsm/l to correlate with better prognosis. Our study is a prospective analysis of one and a half year period with a patient population consisting of children. Our cases and etiologic factors are different from other studies. In our study, the etiologic factors included were infection, hemorrhage, anoxia, and trauma factors. ICP measurement could not be conducted in our study, so treatment was continued considering the serum-Na concentration and osmolarity until clinical improvement was achieved. We have shown better results in Group B and Group C with no significant side effects. The main disadvantage is the fact that in our study direct ICP measurement was not conducted. However, compared with mannitol, the clinical efficacy has also been confirmed by mortality assessment.</p><p>Hypertonic saline has been used more frequently in trauma, intracerebral hemorrhage, burn and stroke patients. Our patient group was different in their etiology of brain edema. Rationale of use of mannitol and HS is similar in both traumatic and non traumatic cerebral edema because all cerebral edemas with varied etiologies usually have vasogenic mechanism. In addition, HS is more effective and safer than mannitol. Greater efficacy of HS compared to mannitol can be speculated by different reflection coefficients of these agents.[<xref ref-type="bibr" rid="CIT1">1</xref>] Because the reflection coefficient for Na and Cl was 1.0, such a side effect in saline treatment may not be expected. To our knowledge, there is rarely any report of HS treatment in edema of anoxic, infectious origin in the recognized literature.</p><p>In terms of the efficacy and side effect profile of the saline treatment in brain edema, the optimum serum-Na concentration and osmolarity are not known. In a retrospective study Peterson <italic>et al</italic>.,[<xref ref-type="bibr" rid="CIT11">11</xref>] though making no comparative analysis, suggested that prognosis in patients with serum-Na concentration within the range of 150-170 mEq/l and serum osmolarity of 300-340 mOsm/l seems to be better. Also, some studies report an inverse relationship between serum-Na concentration and ICP.[<xref ref-type="bibr" rid="CIT9">9</xref>&#x02013;<xref ref-type="bibr" rid="CIT11">11</xref>] There was no significant difference in our patients with Na level of 150-160 and 160-170 mEq/l in terms of duration of the comatose state and mortality. As during the hyperosmolar state, to maintain the osmotic balance, idiogenic hyperosmoles are formed within the cells in 72-96 h.[<xref ref-type="bibr" rid="CIT15">15</xref>&#x02013;<xref ref-type="bibr" rid="CIT18">18</xref>] So after thetermination of HS, serum-Na concentration should be gradually reduced over a period of more than two days.</p><p>Potential side effects of hypertonic saline have been reported:[<xref ref-type="bibr" rid="CIT19">19</xref>] Myelinolysis, acute tubular necrosis and renal failure, subdural hematoma or effusion, heart failure, pulmonary edema, hypokalemia, hyperchloremic metabolic acidosis, coagulopathy, intra-vascular hemolysis, and rebound cerebral edema may occur. Myelinolysis occur more frequently if there is a rapid transition from hyponatremia to hypernatremia. For myelinolysis to occur, a daily serum-Na concentration load of 35-40 mEq/l is required.[<xref ref-type="bibr" rid="CIT20">20</xref>] The region most susceptible to myelinolysis is the pontine white matter with visualized MRI and central pontine myelinolysis is manifested clinically as lethargy and quadriplegia/paresia. We have not observed acute flaccid paralysis/plegia after saline treatment. Especially, in patients with significant degrees of cerebral injury, the clinical assessment of this complication could not be detected possibly by the fact that they had blunted mental status.</p><p>Renal failure, congestive heart failure, pulmonary edema, hypokalemia and phlebitis were not observed in any of our patients. There was no significant tendency for hemolysis or hemorrhage associated with acute fall in the hematocrit level.</p><p>In conclusion, in the treatment of cerebral edema of infectious, anoxic, hemorrhagic and traumatic origin, administration of HS is probably more effective and safer than mannitol. However, to determine just when to initiate treatment, how long to continue treatment, and target serum-Na concentration requires monitoring of the intracranial pressure. Further studies are required to resolve these concerns.</p></sec></body><back><ack><p>I specially thank Dr. Shiromani Singh, statistician for contributing in analyses of data.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><ref id="CIT1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betz</surname><given-names>AL</given-names></name></person-group><article-title>Sodium transport in capillaries isolated from rat brain</article-title><source>J Neurochem</source><year>1983</year><volume>41</volume><fpage>1150</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">6311978</pub-id></element-citation></ref><ref id="CIT2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weed</surname><given-names>LH</given-names></name><name><surname>McKibben</surname><given-names>PS</given-names></name></person-group><article-title>Experimental alteration of brain bulk</article-title><source>Am J Physiol</source><year>1919</year><volume>48</volume><fpage>531</fpage><lpage>55</lpage></element-citation></ref><ref id="CIT3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zornow</surname><given-names>MH</given-names></name></person-group><article-title>Hypertonic saline as a safe and efficacious treatment of intracranial hypertension</article-title><source>J Neurosurg Anesthesiol</source><year>1996</year><volume>8</volume><fpage>175</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8829566</pub-id></element-citation></ref><ref id="CIT4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducey</surname><given-names>JP</given-names></name><name><surname>Mozingo</surname><given-names>DW</given-names></name><name><surname>Lamiell</surname><given-names>JM</given-names></name><name><surname>Okerburg</surname><given-names>C</given-names></name><name><surname>Gueller</surname><given-names>GE</given-names></name></person-group><article-title>A comparison of the cerebral and cardiovascular effects of complete reuscitation with isotonic and hypertonic saline, hetastarch, and whole blood following hemorrhage</article-title><source>J Trauma</source><year>1989</year><volume>29</volume><fpage>1518</fpage><lpage>9</lpage></element-citation></ref><ref id="CIT5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmoker</surname><given-names>JD</given-names></name><name><surname>Zhuang</surname><given-names>J</given-names></name><name><surname>Shackford</surname><given-names>SR</given-names></name></person-group><article-title>Hypertonic fluid resuscitation improves cerebral oxygen delivery and reduces intracranial pressure after hemorrhagic shock</article-title><source>J Trauma</source><year>1991</year><volume>31</volume><fpage>1607</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1749030</pub-id></element-citation></ref><ref id="CIT6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prough</surname><given-names>DS</given-names></name><name><surname>Whitley</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>CL</given-names></name><name><surname>Deal</surname><given-names>DD</given-names></name><name><surname>DeWitt</surname><given-names>DS</given-names></name></person-group><article-title>Regional cerebral blood flow following resuscitation from hemorrhagic shock with hypertonic saline</article-title><source>Anesthesiology</source><year>1991</year><volume>75</volume><fpage>319</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">1677548</pub-id></element-citation></ref><ref id="CIT7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worthley</surname><given-names>LI</given-names></name><name><surname>Cooper</surname><given-names>DJ</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name></person-group><article-title>Treatment of resistant intracranial hypertension with hypertonic saline: Report of two cases</article-title><source>J Neurosurg</source><year>1988</year><volume>68</volume><fpage>478</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">3343621</pub-id></element-citation></ref><ref id="CIT8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>AI</given-names></name><name><surname>Suarez</surname><given-names>JI</given-names></name><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Mirski</surname><given-names>M</given-names></name><name><surname>Schnitzer</surname><given-names>MS</given-names></name><name><surname>Hanley</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><fpage>440</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9504569</pub-id></element-citation></ref><ref id="CIT9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez</surname><given-names>JI</given-names></name><name><surname>Qureshi</surname><given-names>AI</given-names></name><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>MA</given-names></name><name><surname>Schnitzer</surname><given-names>MS</given-names></name><name><surname>Mirski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Treatment of refractory intracranial hypertension with 23.4% saline</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><fpage>1118</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">9635664</pub-id></element-citation></ref><ref id="CIT10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzola</surname><given-names>CA</given-names></name><name><surname>Adelson</surname><given-names>PD</given-names></name></person-group><article-title>Critical care management of head trauma in children</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>S393</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">12528780</pub-id></element-citation></ref><ref id="CIT11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>B</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Marshall</surname><given-names>L</given-names></name></person-group><article-title>Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>1136</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10809295</pub-id></element-citation></ref><ref id="CIT12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>B</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Tung</surname><given-names>H</given-names></name><name><surname>O&#x02019;Quigley</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>1144</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">10809296</pub-id></element-citation></ref><ref id="CIT13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vialet</surname><given-names>R</given-names></name><name><surname>Alban&#x000e8;se</surname><given-names>J</given-names></name><name><surname>Thomachot</surname><given-names>L</given-names></name><name><surname>Antonini</surname><given-names>F</given-names></name><name><surname>Bourgouin</surname><given-names>A</given-names></name><name><surname>Alliez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Isovoleme hypertonic solutes (sodium chloride and mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1683</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12794404</pub-id></element-citation></ref><ref id="CIT14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>P</given-names></name><name><surname>M&#x000fc;nch</surname><given-names>E</given-names></name><name><surname>Vajkoczy</surname><given-names>P</given-names></name><name><surname>Herrmann</surname><given-names>P</given-names></name><name><surname>Quintel</surname><given-names>M</given-names></name><name><surname>Schilling</surname><given-names>L</given-names></name><etal/></person-group><article-title>Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates</article-title><source>Neurol Res</source><year>1999</year><volume>21</volume><fpage>758</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10596385</pub-id></element-citation></ref><ref id="CIT15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Videen</surname><given-names>JS</given-names></name><name><surname>Michaelis</surname><given-names>T</given-names></name><name><surname>Pinto</surname><given-names>P</given-names></name><name><surname>Ross</surname><given-names>BD</given-names></name></person-group><article-title>Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><fpage>788</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">7860762</pub-id></element-citation></ref><ref id="CIT16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;ussinger</surname><given-names>D</given-names></name><name><surname>Laubenberger</surname><given-names>J</given-names></name><name><surname>vom Dahl</surname><given-names>S</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Bayer</surname><given-names>S</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy</article-title><source>Gastroenterology</source><year>1994</year><volume>107</volume><fpage>1475</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">7926510</pub-id></element-citation></ref><ref id="CIT17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lien</surname><given-names>YH</given-names></name><name><surname>Shapiro</surname><given-names>JI</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name></person-group><article-title>Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis</article-title><source>J Clin Invest</source><year>1991</year><volume>88</volume><fpage>303</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2056123</pub-id></element-citation></ref><ref id="CIT18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>JE</given-names></name><name><surname>Goldfinger</surname><given-names>MD</given-names></name></person-group><article-title>Amino acid content of rat cerebral astrocytes adapted to hyperosmotic medium <italic>in vitro</italic></article-title><source>J Neurosci Res</source><year>1990</year><volume>27</volume><fpage>241</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2254966</pub-id></element-citation></ref><ref id="CIT19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Ulatowski</surname><given-names>JA</given-names></name></person-group><article-title>Hypertonic saline solutions in brain injury</article-title><source>Curr Opin Crit Care</source><year>2004</year><volume>10</volume><fpage>126</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15075723</pub-id></element-citation></ref><ref id="CIT20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soupart</surname><given-names>A</given-names></name><name><surname>Penninckx</surname><given-names>R</given-names></name><name><surname>Namias</surname><given-names>B</given-names></name><name><surname>Stenuit</surname><given-names>A</given-names></name><name><surname>Perier</surname><given-names>O</given-names></name><name><surname>Decaux</surname><given-names>G</given-names></name></person-group><article-title>Brain myelinolysis following hypernatremia in rats</article-title><source>J Neuropathol Exp Neurol</source><year>1996</year><volume>55</volume><fpage>106</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">8558165</pub-id></element-citation></ref></ref-list></back></article>